Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link
Dow Jones Industrial Average
) is trading up two points at 18,098 as of Thursday, Mar 5, 2015, 12:36 p.m. ET. During this time, 114.8 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 375 million. The NYSE advances/declines ratio sits at 1,580 issues advancing vs. 1,376 declining with 175 unchanged.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
The Dow component leading the way higher looks to be
), which is sporting a 76-cent gain (+0.8%) bringing the stock to $102.41. This single gain is lifting the Dow Jones Industrial Average by 5.75 points or roughly accounting for 287.5% of the Dow's overall gain. Volume for Johnson & Johnson currently sits at four million shares traded vs. an average daily trading volume of 9.3 million shares.
Johnson & Johnson has a market cap of $284.56 billion and is part of the health care sector and drugs industry. Shares are down 2.8% year-to-date as of Wednesday's close. The stock's dividend yield sits at 2.7%.
Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics.
TheStreet Ratings rates Johnson & Johnson as a
. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
- You can view the full Johnson & Johnson Ratings Report.